Boston, MA – [Date of Publication] – Summit Therapeutics (NASDAQ: SMMT, AIM: SMMT) has announced a significant advancement in its global development program for ivonescimab, an investigational bispecific antibody. The company has initiated the Phase II/III HARMONi-GU1 study, a multi-regional, randomized trial designed to evaluate the efficacy of ivonescimab in combination with enfortumab vedotin (EV) for patients diagnosed with previously untreated locally advanced or metastatic urothelial carcinoma (UC), the most prevalent form of bladder cancer. This trial represents a critical step in addressing a substantial unmet medical need in a challenging disease landscape.
The HARMONi-GU1 study will pit the novel combination of ivonescimab and enfortumab vedotin against the current standard of care, which involves pembrolizumab and enfortumab vedotin. This head-to-head comparison aims to demonstrate the superiority of the investigational regimen in improving patient outcomes. The comprehensive trial is expected to enroll approximately 800 participants in its Phase III stage, with the activation of clinical trial sites anticipated to commence later this year.
The initial Phase II component of HARMONi-GU1 is strategically designed to identify the optimal dose of ivonescimab to be used in conjunction with enfortumab vedotin during the subsequent Phase III expansion. The primary objectives for the pivotal Phase III portion of the study will focus on meticulously measuring progression-free survival (PFS) and overall survival (OS), two key indicators of treatment effectiveness in oncology.
"The initiation of HARMONi-GU1 marks another important step in the continued expansion of our global ivonescimab development programme into additional tumour types where significant unmet need remains," stated Dr. Maky Zanganeh, President and Co-CEO of Summit Therapeutics. "Because both angiogenesis and immune evasion are important features of urothelial carcinoma biology, we believe ivonescimab’s tetravalent, intentionally-engineered PD-1 / VEGF bispecific mechanism offers a compelling scientific rationale for evaluation in bladder cancer."
This latest trial underscores Summit Therapeutics’ commitment to exploring the potential of ivonescimab across a spectrum of oncological indications. The company’s broader development and collaboration activities for ivonescimab currently encompass several other challenging cancer types, including colorectal, kidney, lung, and pancreatic cancers, reflecting a broad-based strategy to maximize the therapeutic impact of this innovative bispecific antibody.
HARMONi-GU1: A Deep Dive into the Trial Design and Rationale
The Unmet Need in Urothelial Carcinoma
Urothelial carcinoma (UC), commonly known as bladder cancer, is a significant global health concern. While it is the most common type of bladder cancer, advanced or metastatic forms often present a grim prognosis, with limited treatment options and a high likelihood of disease progression. For patients diagnosed with previously untreated locally advanced or metastatic UC, the current standard of care has seen incremental improvements, but the quest for more effective and durable treatments remains a paramount priority for oncologists and patients alike.
Ivonescimab: A Novel Bispecific Approach
Ivonescimab, also known internally within Summit’s licensed territories as SMT112, is an investigational bispecific antibody engineered by Akeso. Its unique tetravalent structure is designed to simultaneously target two critical pathways involved in cancer progression: programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF).
- Targeting PD-1: The inhibition of PD-1 is a cornerstone of modern cancer immunotherapy. By blocking the interaction between PD-1 on immune cells and its ligands (PD-L1 and PD-L2) on tumor cells, PD-1 inhibitors can unleash the patient’s own immune system to recognize and attack cancer cells. This approach has revolutionized the treatment of several cancers, including lung, melanoma, and kidney cancer.
- Targeting VEGF: Vascular Endothelial Growth Factor (VEGF) is a key driver of angiogenesis, the process by which tumors develop new blood vessels to sustain their growth and facilitate metastasis. By inhibiting VEGF, ivonescimab aims to starve the tumor of its blood supply, thereby hindering its growth and spread.
The simultaneous blockade of both PD-1 and VEGF pathways is based on a strong scientific rationale. Tumors often employ multiple strategies to evade immune surveillance and promote their growth. Angiogenesis can create an immunosuppressive tumor microenvironment, while immune evasion mechanisms allow cancer cells to escape detection by the immune system. Ivonescimab’s dual-action mechanism is designed to overcome these challenges by both enhancing anti-tumor immunity and disrupting the tumor’s vascular support system.
Enfortumab Vedotin: A Potent Partner
Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein highly expressed on the surface of urothelial carcinoma cells. Upon binding to Nectin-4, EV is internalized by the cancer cell, releasing a cytotoxic agent that induces cell death. EV has demonstrated significant efficacy in patients with advanced UC, particularly those who have previously received chemotherapy and immunotherapy. Its inclusion in the HARMONi-GU1 trial, both in the investigational arm and the control arm, highlights its established role in the treatment paradigm for this disease.
The HARMONi-GU1 Study Design: A Rigorous Evaluation
The HARMONi-GU1 study is structured as a multi-regional, global, randomized, controlled trial. This design ensures that the findings will be applicable across diverse patient populations and healthcare settings.
- Phase II Component: The initial phase will focus on dose optimization. This is crucial for bispecific antibodies like ivonescimab, where finding the right balance between efficacy and tolerability is paramount. The Phase II arm will help determine the recommended Phase III dose of ivonescimab when administered in combination with enfortumab vedotin.
- Phase III Component: Following the dose-finding phase, the study will transition to its pivotal Phase III stage. Here, approximately 800 participants will be randomized to receive either:
- Investigational Arm: Ivonescimab in combination with enfortumab vedotin.
- Control Arm: Pembrolizumab (a PD-1 inhibitor) in combination with enfortumab vedotin.
The choice of pembrolizumab as the comparator in the control arm reflects the current established standard of care in this setting. This direct comparison will provide robust evidence regarding the relative benefits of the investigational combination.
Key Endpoints and Objectives
The primary objectives of the Phase III portion of HARMONi-GU1 are to rigorously assess the impact of the investigational treatment on:
- Progression-Free Survival (PFS): This endpoint measures the time from randomization until disease progression or death from any cause. It is a critical indicator of how well a treatment controls the cancer.
- Overall Survival (OS): This endpoint measures the time from randomization until death from any cause. It is considered the gold standard for evaluating the ultimate benefit of a cancer therapy.
Secondary endpoints will likely include objective response rate (ORR), duration of response (DoR), and safety and tolerability profiles of both treatment regimens.
A Timeline of Development and Global Reach
Summit Therapeutics’ commitment to ivonescimab is evident in its extensive global development program. The initiation of HARMONi-GU1 represents the latest milestone in a journey marked by significant progress and strategic collaborations.
Early Development and Akeso’s Role
Ivonescimab was originally engineered by Akeso, a biopharmaceutical company based in China. This collaboration has been instrumental in bringing ivonescimab from its initial development stages through extensive clinical investigation. The drug has a proven track record of administration to over 4,000 patients in clinical research settings worldwide. Furthermore, in China, where it has received commercial approval for certain indications, ivonescimab has been utilized in over 70,000 individuals, providing a wealth of real-world experience and safety data.
Expanding the Clinical Footprint
Summit Therapeutics holds the rights to develop and commercialize ivonescimab in territories outside of China. This has led to a concerted effort to expand its clinical evaluation into various cancer types where significant unmet medical needs persist. The HARMONi-GU1 trial in urothelial carcinoma is a prime example of this strategic expansion.
Progress in Non-Small Cell Lung Cancer (NSCLC)
Prior to the HARMONi-GU1 announcement, Summit Therapeutics had already achieved significant milestones with ivonescimab in the treatment of non-small cell lung cancer (NSCLC). Four Phase III trials sponsored by Akeso in China, all focusing on NSCLC, have reported positive data. This robust dataset in one of the most common and deadliest cancers has provided valuable insights into ivonescimab’s efficacy and safety profile.
Just last month, Summit Therapeutics released further Phase III trial data for ivonescimab in NSCLC. This data release coincided with the company awaiting a crucial decision from the U.S. Food and Drug Administration (FDA) regarding potential regulatory approval for ivonescimab in this indication. This ongoing regulatory review underscores the potential for ivonescimab to become a significant new treatment option for lung cancer patients.
A Broad Clinical Landscape
Across all its clinical efforts, ivonescimab is currently being assessed in an impressive 16 Phase III studies. This extensive global development program highlights the broad potential of this bispecific antibody and Summit Therapeutics’ dedication to bringing this innovative therapy to patients worldwide. The HARMONi-GU1 trial in urothelial carcinoma adds a vital new dimension to this already comprehensive clinical pipeline.
Official Statements and Scientific Rationale
The initiation of the HARMONi-GU1 trial has been met with enthusiasm from Summit Therapeutics’ leadership, who believe the drug’s unique mechanism of action is well-suited to tackle the complexities of urothelial carcinoma.
Dr. Maky Zanganeh’s Perspective
Dr. Maky Zanganeh, President and Co-CEO of Summit Therapeutics, articulated the strategic importance of this new trial: "The initiation of HARMONi-GU1 marks another important step in the continued expansion of our global ivonescimab development programme into additional tumour types where significant unmet need remains." This statement emphasizes the company’s commitment to pursuing opportunities in cancers with limited effective treatment options.
Dr. Zanganeh further elaborated on the scientific underpinnings of targeting urothelial carcinoma with ivonescimab: "Because both angiogenesis and immune evasion are important features of urothelial carcinoma biology, we believe ivonescimab’s tetravalent, intentionally-engineered PD-1 / VEGF bispecific mechanism offers a compelling scientific rationale for evaluation in bladder cancer." This highlights the dual-action approach as a key differentiator and a promising strategy to overcome the resistance mechanisms often observed in this cancer type.
The rationale is clear:
- Angiogenesis: Bladder tumors, like many solid tumors, rely on the formation of new blood vessels to grow and spread. Inhibiting VEGF, a key mediator of angiogenesis, aims to disrupt this vital supply line.
- Immune Evasion: Cancer cells often develop ways to hide from or suppress the immune system. By blocking PD-1, ivonescimab seeks to "unmask" the cancer cells, making them visible to the immune system’s T-cells.
The combination of these two mechanisms in a single molecule is what makes ivonescimab particularly intriguing for complex cancers like urothelial carcinoma, where multiple pathways contribute to disease progression.
Implications and Future Outlook
The launch of the HARMONi-GU1 trial carries significant implications for patients, the medical community, and Summit Therapeutics as a company.
For Patients:
The initiation of this trial offers new hope for patients diagnosed with previously untreated locally advanced or metastatic urothelial carcinoma. The prospect of a novel treatment combination that could offer improved efficacy over the current standard of care, potentially leading to longer progression-free and overall survival, is a critical development. Participation in clinical trials like HARMONi-GU1 provides access to potentially life-saving investigational therapies and contributes to the advancement of medical knowledge.
For the Medical Community:
If HARMONi-GU1 demonstrates superior efficacy and a manageable safety profile, the combination of ivonescimab and enfortumab vedotin could become a new standard of care for first-line treatment of advanced urothelial carcinoma. This would represent a significant advancement in the management of this disease, offering oncologists a more potent weapon against bladder cancer. The trial’s robust design and large sample size will provide high-quality data for clinical decision-making.
For Summit Therapeutics:
The successful outcome of the HARMONi-GU1 trial would be a transformative event for Summit Therapeutics. It would not only expand the potential market for ivonescimab but also solidify the company’s position as a leader in the development of innovative bispecific antibody therapies. Positive results would likely accelerate regulatory submissions and commercialization efforts, potentially leading to significant revenue growth and shareholder value. The success in urothelial carcinoma, coupled with ongoing progress in NSCLC and other indications, would further validate the company’s strategic focus and its robust pipeline.
The global reach of the HARMONi-GU1 study, with its multi-regional enrollment, is also crucial. It ensures that the findings are generalizable and that the treatment can be made available to patients across different geographical regions, reflecting a commitment to global health equity.
As clinical trial sites begin to activate later this year, the oncological community will be closely watching the progress of the HARMONi-GU1 study. The potential for ivonescimab to make a meaningful difference in the lives of patients battling urothelial carcinoma, a disease with a persistent high unmet need, is substantial. This trial represents a critical juncture in Summit Therapeutics’ journey and a beacon of hope for those affected by bladder cancer.
About the Author
